Peptides and Longevity: The Science of NAD+ and Epitalon

Longevity science is one of the most exciting — and most overhyped — areas in health. Two topics come up constantly: NAD+ and the peptide Epitalon. Here's what the research supports and where it stops.

NAD+ and the aging cell

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in a vast number of cellular reactions, with a central role in supporting mitochondrial function — the energy machinery of your cells (npj Metabolic Health and Disease). Research has consistently shown that NAD+ levels decline with normal aging in both mice and humans, and that this decline is closely linked to the aging process (PMC review).

That's why raising NAD+ has become such a focus. Studies in animals have shown that supplementing with NAD+ precursors (such as nicotinamide riboside and nicotinamide mononucleotide) can restore NAD+ toward youthful levels (PMC). The mechanism is well-supported; what's still being worked out is how much these interventions translate into measurable longevity or healthspan benefits in humans.

Epitalon and telomeres

Telomeres are the protective caps at the ends of chromosomes that shorten as cells divide, and telomere length is considered a biomarker of aging (Biogerontology study). Epitalon (also called epithalon, sequence AEDG) is a synthetic tetrapeptide first derived from a pineal gland extract and developed in Russia.

A 2025 peer-reviewed study from Brunel University London found that Epitalon extended telomere length in healthy human cell lines by upregulating telomerase activity (Biogerontology, 2025). This builds on earlier work showing Epitalon can induce telomerase activity and telomere elongation in human somatic cells. It's a compelling mechanism. But most of this evidence comes from cell cultures and animal models, plus older Russian clinical work — and Epitalon remains a research-use compound, not an approved drug.

Reading the evidence honestly

Both NAD+ decline and telomere shortening are real, well-documented hallmarks of aging. The interventions that target them have promising biology and early data. What they don't yet have is the body of large, rigorous human longevity trials that would let anyone make strong claims. That gap is exactly where careful, evidence-led thinking matters most.

FAQ

Does NAD+ really decline with age?

Yes. Research in both animals and humans shows NAD+ levels fall with aging, which is part of why NAD+ precursors are widely studied.

Is Epitalon FDA-approved?

No. Epitalon is a synthetic peptide available for research use; it is not an approved drug, and most evidence is from lab and animal studies.

Can these reverse aging?

No responsible reading of the evidence supports that claim. The biology is promising and the human longevity data is still early.